Princeton-based drug developer Covance announced Tuesday its fiscal second-quarter results rose from the same period in 2013.
Covance said in a news release that pro forma earnings were 95 cents per diluted share, an increase of 21.5 percent from the year-ago period. Net revenue reached $639 million, up 8 percent from the year before.
"In the second quarter, a stronger-than-expected performance in early development and continued strong growth in central laboratories more than offset lower-than-expected growth in clinical development," Joe Herring, chairman and CEO, said in the release.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy